Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 55%
Buy 32%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is well-positioned for long-term growth with a strong technology portfolio, expanding clinical and economic case for CGM adoption in the T2NIT population, and an anticipated CMS coverage expansion. The company's recent CONNECT and ADA data demonstrate the benefits and synergies of CGM in combination with GLP-1 and SGLT-2 therapies. Additionally, strong margins and rising NRx figures indicate positive growth potential in both the US and international markets, with a goal of driving CGM adoption across all aspects of diabetes care.

Bears say

DexCom is facing several challenges, including pricing pressures from payors and potential delays in commercializing new products. Additionally, the company's revenue growth for 2026 was largely due to fuel-related impacts, rather than organic growth. Furthermore, DexCom's revenue for the first quarter of 2026 was mixed, with US sales missing expectations and the company relying on international sales for growth. These factors contribute to our negative outlook on the company's stock.

DexCom (DXCM) has been analyzed by 22 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 32% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 22 analysts, DexCom (DXCM) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.